| Literature DB >> 22826640 |
Somchai Amornyotin1, Somchai Leelakusolvong, Wiyada Chalayonnawin, Siriporn Kongphlay.
Abstract
INTRODUCTION: Endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasonography (EUS) procedures in elderly patients are on the rise, and they play an important role in the diagnosis and management of various gastrointestinal diseases. The use of deep sedation in these patients has been established as a safe and effective technique in Western countries; however, it is uncertain if the situation holds true among Asians. The present study aimed to evaluate the age-dependent safety analysis and clinical efficacy of propofol-based deep sedation (PBDS) for ERCP and EUS procedures in adult patients at a World Gastroenterology Organization (WGO) Endoscopy Training Center in Thailand.Entities:
Keywords: deep sedation; developing country; elderly; endoscopic retrograde cholangiopancreatography; endoscopic ultrasonography; propofol
Year: 2012 PMID: 22826640 PMCID: PMC3401056 DOI: 10.2147/CEG.S31275
Source DB: PubMed Journal: Clin Exp Gastroenterol ISSN: 1178-7023
Characteristics of patients, sedation time, and indications of procedures
| Group A | Group B | Group C | |
|---|---|---|---|
| Number of patients (%) | 252 (51.3) | 209 (42.6) | 30 (6.1) |
| Age (years) (SD) | 45.1 (11.1) | 71.7 (4.3) | 84.6 (4.2) |
| Sex (%) | |||
| Male | 116 (46.0) | 109 (52.2) | 14 (46.7) |
| Female | 136 (54.0) | 100 (47.8) | 16 (53.3) |
| Weight (kg) (SD) | 55.6 (9.1) | 53.8 (9.1) | 49.3 (7.3) |
| ASA physical status (%) | |||
| I | 164 (65.1) | 2 (1.0) | 0 |
| II | 78 (31.0) | 160 (76.6) | 16 (53.3) |
| III | 10 (4.0) | 46 (22.0) | 14 (46.7) |
| IV | 0 | 1 (0.5) | 0 |
| Sedation time (min) (SD) | 47.3 (20.3) | 51.2 (30.9) | 43.2 (25.0) |
| Indications of procedure (%) | |||
| Cholelithiasis | 26 (10.3) | 38 (18.2) | 9 (30.0) |
| Pancreatitis | 8 (3.2) | 22 (10.5) | 16 (16.7) |
| Gastric tumor | 42 (16.7) | 32 (15.3) | 4 (13.3) |
| Pancreatic tumor | 85 (33.7) | 42 (20.1) | 3 (10.0) |
| Hepatobiliary abnormality | 38 (15.1) | 28 (13.4) | 3 (10.0) |
| Abdominal pain | 21 (8.3) | 4 (1.9) | 0 |
| Others | 32 (12.7) | 43 (20.6) | 6 (20.0) |
Notes: Group A: age < 65 years; group B: age 65–80 years; group C: age > 80 years.
Mean dose of sedative agents categorized by age
| Group A (252) | Group B (209) | Group C (30) | |
|---|---|---|---|
| n (%) | 252 (100.0) | 209 (100.0) | 30 (100.0) |
| mg/kg/hr (SD, range) | 6.3 (2.5), 2.5–18.3 | 5.0 (2.7), 1.0–18.5 | 4.0 (1.6), 1.8–9.2 |
| n (%) | 237 (94.0) | 200 (95.7) | 28 (93.3) |
| mg/kg/hr (SD, range) | 0.001 (0.001), 0.000–0.006 | 0.001 (0.001), 0.000–0.008 | 0.001 (0.001), 0.000–0.004 |
| n (%) | 11 (4.4) | 5 (2.4) | 0 |
| mg/kg/hr (SD, range) | 0.7 (0.3), 0.2–1.2 | 0.7 (0.5), 0.4–1.5 | |
| n (%) | 231 (91.7) | 186 (89.0) | 25 (83.3) |
| mg/kg/hr (SD, range) | 0.05 (0.04), 0.01–0.36 | 0.03 (0.02), 0.00–0.19 | 0.03 (0.03), 0.01–0.15 |
Notes: Group A: age < 65 years; group B: age 65–80 years; group C: age > 80 years.
Mean dose of sedative agents categorized by ASA physical status (mg/kg/hr, SD, range)
| ASA I–II | ASA III–IV | |||||
|---|---|---|---|---|---|---|
|
|
| |||||
| Group A (242) | Group B (162) | Group C (16) | Group A (10) | Group B (47) | Group C (14) | |
| Propofol | 6.3 (2.6) | 5.3 (2.6) | 4.5 (2.0) | 5.6 (2.1) | 4.3 (2.8) | 3.8 (1.4) |
| 2.5–18.3 | 1.4–16.0 | 1.8–9.2 | 2.5–10.5 | 1.0–18.5 | 1.8–6.3 | |
| Fentanyl | 0.001 (0.001) | 0.001 (0.001) | 0.001 (0.001) | 0.001 (0.001) | 0.001 (0.001) | 0.002 (0.001) |
| 0.000–0.006 | 0.000–0.008 | 0.000–0.004 | 0.000–0.002 | 0.000–0.007 | 0.000–0.004 | |
| Pethidine | 0.7 (0.3) | 0.7 (0.5) | 0 | 0 | 0 | 0 |
| 0.3–1.2 | 0.4–1.5 | |||||
| Midazolam | 0.05 (0.04) | 0.03 (0.02) | 0.03 (0.04) | 0.04 (0.02) | 0.04 (0.04) | 0.04 (0.02) |
| 0.01–0.36 | 0.00–0.11 | 0.01–0.15 | 0.02–0.09 | 0.01–0.19 | 0.01–0.07 | |
Notes: Group A: age < 65 years; group B: age 65–80 years; group C: age > 80 years.
Abbreviation: ASA, American Society of Anesthesiologists.
Combination of sedative agents used (n, %)
| Group A (252) | Group B (209) | Group C (30) | |
|---|---|---|---|
| Propofol–pethidine | 1 (0.4) | 0 | 0 |
| Propofol–midazolam | 4 (1.6) | 4 (1.9) | 2 (6.7) |
| Propofol–fentanyl | 20 (7.9) | 23 (11.0) | 5 (16.7) |
| Propofol–midazolam–fentanyl | 217 (86.1) | 177 (84.7) | 23 (76.7) |
| Propofol–midazolam–pethidine | 10 (4.0) | 5 (2.4) | 0 |
Notes: Group A: age < 65 years; group B: age 65–80 years; group C: age > 80 years.
Sedation-related adverse events and procedure-related complications (n, %)
| Group A (252) | Group B (209) | Group C (30) | ||
|---|---|---|---|---|
| Overall | 83 (32.9) | 69 (33.0) | 11 (36.7) | 0.917 |
| Respiratory | 8 (3.2) | 6 (2.9) | 1 (3.3) | 0.978 |
| Hypoxia (SpO2 < 90%) | 3 (1.2) | 2 (1.0) | 0 | 0.823 |
| Upper airway obstruction | 5 (2.0) | 4 (1.9) | 1 (3.3) | 0.873 |
| Cardiovascular | 73 (29.0) | 62 (29.7) | 10 (33.3) | 0.883 |
| Hypotension | 66 (26.2) | 56 (26.8) | 10 (33.3) | 0.706 |
| Hypertension | 2 (0.8) | 3 (1.4) | 0 | 0.672 |
| Bradycardia | 4 (1.6) | 3 (1.4) | 0 | 0.786 |
| Arrhythmia | 1 (0.4) | 0 | 0 | 0.622 |
| Procedure-related | 2 (0.8) | 1 (0.5) | 0 | 0.826 |
| Duodenal perforation | 0 | 1 (0.5) | 0 | 0.509 |
| Hemorrhage | 1 (0.4) | 0 | 0 | 0.622 |
| Pancreatitis | 1 (0.4) | 0 | 0 | 0.622 |
Notes: Group A: age < 65 years; group B: age 65–80 years; group C: age > 80 years.